Emergence of SARS-CoV-2 Delta Variant and Effect of Nonpharmaceutical Interventions, British Columbia, Canada

被引:1
|
作者
Chan, Y. L. Elaine [1 ,2 ]
Irvine, Michael A. [1 ,3 ]
Prystajecky, Natalie [1 ,4 ]
Sbihi, Hind [1 ,4 ]
Taylor, Marsha [1 ]
Joffres, Yayuk [1 ]
Schertzer, Andrea [1 ,2 ]
Rose, Caren [1 ,4 ]
Dyson, Louise [5 ,6 ]
Hill, Edward M. [5 ,6 ]
Tildesley, Michael [5 ,6 ]
Tyson, John R. [1 ]
Hoang, Linda M. N. [1 ,4 ]
Galanis, Eleni [1 ,4 ]
机构
[1] British Columbia Ctr Dis Control, 655 W 12th Ave, Vancouver, BC V5Z 4R4, Canada
[2] Publ Hlth Agcy Canada, Ottawa, ON, Canada
[3] Simon Fraser Univ, Burnaby, BC, Canada
[4] Univ British Columbia, Vancouver, BC, Canada
[5] Univ Warwick, Coventry, W Midlands, England
[6] Joint Univ Pandem & Epidemiol Res, Bristol, Avon, England
关键词
D O I
10.3201/eid2910.230055
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In British Columbia, Canada, initial growth of the SARS-CoV-2 Delta variant was slower than that reported in other jurisdictions. Delta became the dominant variant (>50% prevalence) within approximate to 7-13 weeks of first detection in regions within the United Kingdom and United States. In British Columbia, it remained at <10% of weekly incident COVID-19 cases for 13 weeks after first detection on March 21, 2021, eventually reaching dominance after 17 weeks. We describe the growth of Delta variant cases in British Columbia during March 1-June 30, 2021, and apply retrospective counterfactual modeling to examine factors for the initially low COVID-19 case rate after Delta introduction, such as vaccination coverage and nonpharmaceutical interventions. Growth of COVID-19 cases in the first 3 months after Delta emergence was likely limited in British Columbia because additional nonpharmaceutical interventions were implemented to reduce levels of contact at the end of March 2021, soon after variant emergence.
引用
收藏
页码:1999 / 2007
页数:9
相关论文
共 50 条
  • [21] Temperature and population density influence SARS-CoV-2 transmission in the absence of nonpharmaceutical interventions
    Smith, Thomas P.
    Flaxman, Seth
    Gallinat, Amanda S.
    Kinosian, Sylvia P.
    Stemkovski, Michael
    Unwin, H. Juliette T.
    Watson, Oliver J.
    Whittaker, Charles
    Cattarino, Lorenzo
    Dorigatti, Ilaria
    Tristem, Michael
    Pearse, William D.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (25)
  • [22] Community Antibiotic Use at the Population Level During the SARS-CoV-2 Pandemic in British Columbia, Canada
    Mamun, Abdullah A.
    Saatchi, Ariana
    Xie, Max
    Lishman, Hannah
    Blondel-Hill, Edith
    Marra, Fawziah
    Patrick, David M.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (06):
  • [23] A focus on the spread of the delta variant of SARS-CoV-2 in India
    Novelli, Giuseppe
    Colona, Vito
    Pandolfi, Pier
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2021, 153 (05) : 537 - 541
  • [24] Hospitalisation associated with SARS-CoV-2 delta variant in Denmark
    Bager, Peter
    Wohlfahrt, Jan
    Rasmussen, Morten
    Albertsen, Mads
    Krause, Tyra Grove
    LANCET INFECTIOUS DISEASES, 2021, 21 (10): : 1351 - 1351
  • [25] Airborne transmission of the Delta variant of SARS-CoV-2 in an auditorium
    Huang, Jianxiang
    Hao, Tongping
    Liu, Xiao
    Jones, Phil
    Ou, Cuiyun
    Liang, Weihui
    Liu, Fuqiang
    BUILDING AND ENVIRONMENT, 2022, 219
  • [26] Confronting the Delta Variant of SARS-CoV-2, Summer 2021
    del Rio, Carlos
    Malani, Preeti N.
    Omer, Saad B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (11): : 1001 - 1002
  • [27] SARS-CoV-2 Transmission and Prevention in the Era of the Delta Variant
    Meyerowitz, Eric A.
    Richterman, Aaron
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2022, 36 (02) : 267 - 293
  • [28] Transmission of SARS-CoV-2 before and after symptom onset: impact of nonpharmaceutical interventions in China
    Bushman, Mary
    Worby, Colin
    Chang, Hsiao-Han
    Kraemer, Moritz U. G.
    Hanage, William P.
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2021, 36 (04) : 429 - 439
  • [29] What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant?
    Wilder-Smith, Annelies
    LANCET INFECTIOUS DISEASES, 2022, 22 (02): : 152 - 153
  • [30] Transmission of SARS-CoV-2 before and after symptom onset: impact of nonpharmaceutical interventions in China
    Mary Bushman
    Colin Worby
    Hsiao-Han Chang
    Moritz U. G. Kraemer
    William P. Hanage
    European Journal of Epidemiology, 2021, 36 : 429 - 439